Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.09.15.751727

miRNA-mediated regulation of lineage plasticity in YY1 knockout pro-B cells

Abstract

Yin Yang 1 (YY1) is a multifunctional transcription factor involved in chromatin organization and gene regulation. While the mechanisms by which YY1 controls B cell lineage development have been explored at the transcriptional level, little is known at the post-transcriptional level. To address this, we performed integrated analyses combining bulk transcriptomics, miRNA profiling, and single-cell transcriptomics to identify YY1-dependent regulatory networks at the pro-B cell stage. YY1 knockout (KO) in pro-B cells leads to reduced B-lineage commitment and activation of genes associated with alternative hematopoietic fates. Our integrative analyses suggest that these changes are organized in part through coordinated miRNA-mRNA regulatory networks. In wild-type (WT) pro-B cells, miRNAs such as miR-10a-5p, miR-674-5p, and miR-21a-5p maintain B cell identity by suppressing RNAs linked to other lineages. In contrast, in YY1 KO pro-B cells increased expression of miRNAs including miR-15b-5p, miR-342-5p, and miR-34a-5p target pathways required for B cell development, proliferation, and survival thus reducing B lineage identity. Together, these findings suggest that YY1 preserves B cell identity through coordinated regulation of transcriptional and post-transcriptional programs, with YY1-dependent miRNA networks contributing to the maintenance of B cell-associated gene expression and restriction of alternative lineage programs. Among these, miR-15b-5p emerged as a central regulator predicted to regulate Bcl6b and E2f family transcription factors that control proliferative and transcriptional programs critical for early B cell development. At single-cell resolution, YY1 KO pro-B cells grown on OP9-DL4 feeders that provide Notch signaling displayed marked transcriptional heterogeneity and loss of pro-B lineage commitment. Pseudotime analysis revealed a branched developmental landscape, with cells diverging toward monocyte, macrophage, and dendritic cell fates rather than a consistent B cell differentiation trajectory. Collectively, these findings establish YY1 as a central regulator of lineage commitment integrating transcriptional and miRNA-mediated post-transcriptional mechanisms to regulate B cell identity.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Bano, N., Naiyer, S., Sanyal, S., Hodawadekar, S., Atchison, M. L.. 2026-09-17. miRNA-mediated regulation of lineage plasticity in YY1 knockout pro-B cells. https://doi.org/10.64898/2026.09.15.751727

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Single-AAV-mediated cardiomyocyte-specific adenine base editing ameliorates cardiac hypertrophy in vivo

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, frequently accompanied by cardiac hypercontractility, diastolic dysfunction, heart failure and sudden cardiac death. The disease is predominantly caused by pathogenic variants in genes encoding sarcomeric proteins and current therapeutic strategies largely focus on symptom management. Adeno-associated virus-based (AAV) delivery of base editing tools has emerged as an alternative strategy that acts directly on the genetic cause of disease. However, canonical SpCas9-based editors are too large to package into a single-AAV vector which mandates dual-AAV approaches that require higher overall vector doses with elevated toxicity risk and increased manufacturing costs. Here, we report the development and application of a single vector approach for cardiomyocyte-specific adenine base editing to correct a Dutch founder mutation in MYBPC3 (c.2827C>T, p.Arg943Ter) that causes HCM. We systematically compared compact base editors in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and selected the most efficient configuration, which reversed disease-associated hypercontractility in engineered human myocardium (EHM). To fit the editor/guide construct in a single-AAV vector, we screened a library of rationally designed small chimeric promoters and identified 6C2 to effectively drive expression in hiPSC-CMs and cardiac tissue of both mice and non-human primates (NHP) with exceptional specificity. Delivered in a single next-generation cardiotropic AAV capsid, we achieved therapeutic correction in an HCM mouse model at doses 20-fold below published dual-AAV cardiomyopathy base editing approaches. These results establish cardiomyocyte-specific, single vector-mediated base editing as a viable therapeutic strategy for inherited cardiomyopathies.

molecular biology↗

Engineered Miniature ParTasR Enables Efficient PAMless Genome Editing

TIGR-Tas system holds great promise for genome-engineering applications owing to its compact size and PAMless targeting capability. However, its low editing efficiency in mammalian cells severely limits its broader utility. Here, we engineered a highly active variant of ParTasR, termed eTasR, through structure-guided rational design of ParTasR combined with fusion to the exonuclease TREX2. eTasR increased mammalian editing efficiency from the original 4.29% to 48.94% with an average 26.52-fold increase, significantly surpassing the efficiency of SpRY, a reported version of PAM-free nuclease. More importantly, single-AAV delivery enabled efficient Hpd disruption in vivo, resulting in robust phenotypic rescue. Thus, eTasR provides a compact, PAMless and highly efficient platform for genome editing and therapeutic applications.

molecular biology↗

Enhancing pancreatic islet cell survival via NMDAR antagonist-driven ROR1 activation as revealed by phosphoproteomics

NMDA receptors (NMDARs) control function and survival not only of neurons, but also of insulin-producing pancreatic beta cells. Since insufficient insulin secretion and beta cell death are key events during diabetes development, targeting NMDARs offers a therapeutic approach. Specifically, the NMDAR antagonist dextrorphan (DXO) increases glucose-stimulated insulin secretion in clinical trials. Furthermore, treatment with DXO or optimized DXO derivatives prevents pancreatic islet cell death upon diabetogenic insults. Nonetheless, the signaling pathways induced by NMDAR inhibition are poorly understood. Here, we use complementary approaches, phosphoproteomics and tyrosine kinase profiling, to demonstrate that DXO and its derivatives rapidly regulate multiple intracellular signaling clusters, including mTOR and ERK signaling, in pancreatic islets. Notably, mTOR inhibition, but not ERK inhibition, is sufficient to negate DXO's protective effects. Further, we show that activation of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) is a universal event upon NMDAR inhibition in islets. Simultaneous knockdown of Ror1/ROR1 and its paralogue Ror2/ROR2 compromises the viability of both mouse and human islets, highlighting the ROR1/2 signaling axis as a promising avenue for enhancing beta cell survival.

molecular biology↗